Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks.
about
Aminoglycoside Prescribing and Surveillance in Cystic FibrosisInhaled antibiotics for long-term therapy in cystic fibrosisNebulised anti-pseudomonal antibiotics for cystic fibrosisInhaled therapy in cystic fibrosis: agents, devices and regimensColistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapyRecent advances in cystic fibrosisSystematic review of antistaphylococcal antibiotic therapy in cystic fibrosis.Evidence-based medicine in cystic fibrosis: how should practice change?Urinary N-acetyl-beta-D-glucosaminidase activity in patients with cystic fibrosis on long-term gentamicin inhalation.Lung infections. 3. Pseudomonas aeruginosa and other related species.Nebulized antibiotic therapy: the evidence.Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.Delivery of antibiotics to the respiratory tract: an update.Pulmonary Pharmacokinetics of Colistin Following Administration of Dry Powder Aerosols in Rats.Evidence-based pediatric pulmonary medicine: how can it help?Nebulised antibiotics for adults with cystic fibrosis.Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis.Bronchoconstriction following nebulised colistin in cystic fibrosis.Clinical outcome in relation to care in centres specialising in cystic fibrosis. Cross infection with Pseudomonas aeruginosa is unusualIs prolonged rotavirus infection a common cause of protracted diarrhoea?Influence of a pulmonary surfactant on the in vitro activity of tobramycin against Pseudomonas aeruginosaEvidence for using nebulised antibiotics in cystic fibrosis.Controlled release antibiotics for dry powder lung delivery.Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.
P2860
Q22306318-08285842-2B16-428E-B05C-54B4936E25BCQ24235635-5558F87B-CB96-471D-B006-048FB091FF4AQ24247996-081A141A-2D90-45F4-803B-6BEE37B50A8FQ26797450-6C66B93A-C04F-406F-B77F-0417B1B80776Q27014993-137CC63B-B064-4BF2-B132-155141448120Q28367361-1DF219F0-C86F-45FE-89E6-414EDB1A6839Q33598905-02A127E4-4734-4EFC-B66E-5DC38ABF8672Q34804108-51C10830-DDA1-490C-9735-6F2BF7853437Q35259843-4D95F73C-F3A1-4C6A-ADAF-3FCE40816B32Q35532283-E3F7DCF8-0240-4518-A60A-193ECAB25AE8Q36310044-C8CFBD98-4A5C-494C-B73E-4290A462C9BEQ37029217-B6F09B71-CF1D-4EDA-BCFA-321071BA8E02Q37564542-77121A52-BBE9-40EF-B0C4-DC86A3A11BB1Q40093588-82DAC3FB-988D-497F-8657-3AF9A5913C06Q41727273-FB0DB214-B828-4DE1-9644-FD9361E93DA2Q41810487-5A1A7926-6420-48D0-A1E1-19A81B25BCB6Q41847225-AC80EBC4-B7DC-4A59-BABC-12E5DA1F409FQ41906174-5AC15073-64AA-4043-AF21-26FDCBE5E706Q42002107-BD28082E-6313-4533-AB46-E303CCE55439Q42143890-7EA10CD1-8874-409A-B4F2-92C7C64F17ECQ42729296-9716CDC9-4A8A-4D6D-AE0A-B26323E05637Q43102413-0D62075C-1E3C-4BE9-A8BE-595166E07E3DQ43298353-27F6E081-97CB-4999-B09B-A3E16385013BQ45161536-6A3F85E1-FFE4-4DEE-BD80-D60A97C37D61
P2860
Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks.
description
1996 nî lūn-bûn
@nan
1996 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Nebulised antipseudomonal anti ...... nalysis of benefits and risks.
@ast
Nebulised antipseudomonal anti ...... nalysis of benefits and risks.
@en
type
label
Nebulised antipseudomonal anti ...... nalysis of benefits and risks.
@ast
Nebulised antipseudomonal anti ...... nalysis of benefits and risks.
@en
prefLabel
Nebulised antipseudomonal anti ...... nalysis of benefits and risks.
@ast
Nebulised antipseudomonal anti ...... nalysis of benefits and risks.
@en
P2093
P2860
P356
P1433
P1476
Nebulised antipseudomonal anti ...... nalysis of benefits and risks.
@en
P2093
P2860
P304
P356
10.1136/THX.51.4.364
P407
P577
1996-04-01T00:00:00Z